Fair value measurements and investments (Tables)

3 Months Ended

Mar. 31, 2025

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value measurements of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

	March 31, 2025											December 31, 2024
(U.S. Dollars, in thousands)	Level 1		Level 2			Level 3			Total			Total
									(Unaudited)
Assets
Neo Medical convertible loan agreement	$	—	$	—		$	—		$	—		$	—
Neo Medical preferred equity securities		—		—			—			—			—
Total	$	—	$	—		$	—		$	—		$	—
Liabilities
Lattus contingent consideration	$	—	$	—		$	(14,790	)	$	(14,790	)	$	(15,400	)
Deferred compensation plan		—		(1,719	)		—			(1,719	)		(1,703	)
Total	$	—	$	(1,719	)	$	(14,790	)	$	(16,509	)	$	(17,103	)

Schedule of Reconciliation of Investments in Equity Securities

The table below presents a reconciliation of the beginning and ending balances of the Company’s investment in Neo Medical preferred equity securities:

(Unaudited, U.S. Dollars, in thousands)	2025		2024
Fair value of Neo Medical preferred equity securities at January 1	$	—	$	4,951
Foreign currency remeasurement recognized in other income (expense), net		—		—
Unrealized loss recognized in other expense, net		—		—
Fair value of Neo Medical preferred equity securities at March 31	$	—	$	4,951
Cumulative unrealized loss on Neo Medical preferred equity securities	$	—	$	(720	)

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

(Unaudited, U.S. Dollars, in thousands)	2025			2024
Lattus Contingent Consideration estimated fair value at January 1	$	15,400		$	8,500
Change in fair value recognized in acquisition-related amortization, impairment, and remeasurement		(610	)		1,170
Lattus Contingent Consideration estimated fair value at March 31	$	14,790		$	9,670

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Schedule of Reconciliation For Convertible Loans Measured At Fair Value Using Significant Unobservable Inputs

(Unaudited, U.S. Dollars, in thousands)	2025		2024
Fair value of Neo Medical Convertible Loan at January 1	$	—	$	6,760
Gain recognized in other comprehensive income (loss)		—		1,671
Interest recognized in interest income, net		—		135
Foreign currency remeasurement recognized in other income (expense), net		—		(471	)
Expected credit loss recognized in other income (expense), net		—		260
Fair value of Neo Medical Convertible Loan at March 31	$	—	$	8,355
Contractual value of Neo Medical Convertible Loan at March 31	$	—	$	6,683
Allowance for credit loss recognized in other income (expense), net		—		—
Amortized cost basis of Neo Medical Convertible Loan at March 31	$	—	$	6,683

Schedule of Changes in Valuation of Securities

The following table provides quantitative information related to certain key assumptions utilized within the valuation as of March 31, 2025:

(Unaudited, U.S. Dollars, in thousands)	Fair Value as of  March 31, 2025		Unobservable inputs	Estimate
Lattus Contingent Consideration	$	14,790	Counterparty discount rates	10.4% - 10.8%
			Revenue risk-adjusted discount rates	7.2% - 7.7%